SCHEMBL5619686

SCHEMBL5619686

O=C(Nc1cccnc1)c1c(OC(F)F)ccc2oc3ccc(OC(F)(F)F)cc3c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
ABL1 P00519 6/20 0.45
OPRM1 P35372 1/20 0.45
KCNH2 Q12809 1/20 0.45
LMNA P02545 2/20 0.43
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5026497 0.87 PDE4D (0.52) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL5022678 0.86 KDM4E (0.49) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL5016436 0.77 SMN1; SMN2 (0.50) NPC1RAB9ALMNAMAPTKDM4E
SCHEMBL5023300 0.76 PDE4D (0.53) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL5017920 0.76 PDE4D (0.55) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5018084 0.74 NPC1 (0.62) NPC1RAB9ALMNAMAPTKDM4E
SCHEMBL5025326 0.74 LMNA (0.55) NPC1RAB9ALMNAMAPTKDM4E
SCHEMBL5023292 0.71 PDE4D (0.51) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL5026608 0.71 KMT2A (0.57) NPC1RAB9ALMNAMAPTKDM4E
SCHEMBL12978270 0.70 RAB9A (0.74) NPC1RAB9AABL1OPRM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238725-B2 Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2007-07-03 US disclosed
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them LTC4S, TSLP, GPR119 NPC1 853/4885RAB9A 3448/4885PDE4A 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.